- Achilles Therapeutics PLC at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) TranscriptApr 24, 2023
- Achilles Therapeutics PLC at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 14, 2023
- Achilles Therapeutics PLC at Eqt Life Sciences BioCapital Europe TranscriptMar 09, 2023
- Achilles Therapeutics PLC at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Achilles Therapeutics PLC ESMO IO Webcast Call TranscriptDec 06, 2022
- Achilles Therapeutics PLC at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Achilles Therapeutics PLC to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting - Fireside Chat TranscriptApr 14, 2022
- Achilles Therapeutics PLC at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Achilles Therapeutics PLC SITC and Corporate Update Call TranscriptNov 12, 2021
Achilles Therapeutics PLC at JPMorgan Healthcare Conference Transcript
Good morning. I'm Eric Joseph, senior biotech analyst with J.P. Morgan. And our next presenting company is Achilles Therapeutics. And presenting on behalf of the company is CEO, Iraj Ali. (Conference Instructions)
So with that, Iraj?
Thanks, Eric. Wonderful to have this opportunity to tell you a little bit more about Achilles Therapeutics' progress and plans to date. So I draw your attention to the forward-looking statements and disclaimers to review in your own time.
So Achilles is a clinical stage oncology business, developing multiple programs in using a T cell therapy to address late-stage metastatic disease. We are targeting a novel class of antigen, the clonal neoantigen that we believe can unlock transformational efficacy. And we believe that we can show here today the beginnings of the concept of going from tumor genetics to target engagement, and that can be designed and demonstrated through to the patient.
The company was founded in early 2016
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)